VALNEVA SE WKN: A0MVJZ ISIN: FR0004056851 Forum: Aktien Thema: Hauptdiskussion

je ne parle pas allemand

VALNEVA : French vaccine company Valneva announced, on Tuesday, its Chikungunya vaccine has been authorized in the EU for adolescents aged 12 and above.

In Deutsch wäre schön Dank

VALNEVA <VLS.PA> a annoncé mardi que son vaccin contre le Chikungunya était désormais autorisé chez les adolescents dans l'Union européenne.

Welche Meldung? Hab' ich was verpasst?

Bei mir kam die Meldung 17:49

Schau halt mal, ob Du dagegen klagen kannst 😄

Paris ist mit 3,2 aus dem Handel

sorry, aber die Meldung kam erst nach Börseschluss Paris. Morgen sieht man die Auswirkung.

Das ist doch ein Aprilscherz 😛 Kurz hoch und gleich wieder runter 🤷🏻‍♂️

Wahnsinn Wahnsinn

3 Jahres Chart sagt schon alles aus

Was denn jetzt

gleich rot

Chikungunya has become an increasingly pressing public health issue, with outbreaks currently ongoing in India, Brazil and the French Island of La Réunion. Valneva announced last week that it has responded to the French government's call for supply of IXCHIQ(®) in La Réunion and that it will provide 40,000 doses to the Island's wholesalers, with an option to provide more(5). Dr. Richard Hatchett, Chief Executive Officer of the Coalition for Epidemic Preparedness Innovations (CEPI), commented, 'Cases of chikungunya are increasing around the world, making populations of all ages vulnerable to the disease's long-term debilitating effects, such as prolonged joint plan and inflammation. EC's marketing authorization for use of IXCHIQ(®) in adolescents in the EU is an important steppingstone that could help accelerate the approval of the vaccine in this age group in other regions, including areas where the disease is endemic.'

IXCHIQ(®) is the world's first licensed chikungunya vaccine available to address this significant unmet medical need. In addition to its approval in adolescents and adults in the EU, it is approved in the United States (U.S.)(2), Canada(3) and the United Kingdom (U.K.)(4) for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. Similar label extension applications to adolescents were also submitted in the U.S., Canada and the U.K. Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, said, 'Given the substantial risk that chikungunya presents to individuals residing in or traveling to endemic regions, it's imperative to ensure the vaccine is available to all age groups. This adolescent approval marks a crucial milestone toward introducing a more robust preventative solution against chikungunya in the EU. Broader accessibility will help provide protection and mitigate the burden of this debilitating illness, which is continuing to spread in areas that were previously unaffected.'